These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24476011)

  • 1. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy.
    Shi KQ; Tang JZ; Zhu XL; Ying L; Li DW; Gao J; Fang YX; Li GL; Song YJ; Deng ZJ; Wu JM; Tang KF
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1149-58. PubMed ID: 24476011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease.
    Gu Q; Cen L; Lai J; Zhang Z; Pan J; Zhao F; Yu C; Li Y; Chen C; Chen W; Shen Z
    Eur J Clin Invest; 2021 Feb; 51(2):e13446. PubMed ID: 33128454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
    Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
    Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
    J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy.
    Jia S; Zhao Y; Liu J; Guo X; Chen M; Zhou S; Zhou J
    Front Pediatr; 2021; 9():784221. PubMed ID: 35087774
    [No Abstract]   [Full Text] [Related]  

  • 9. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
    Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
    Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
    J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Mendes LC; Ferreira PA; Miotto N; Zanaga L; Lazarini MS; Gonçales ESL; Pedro MN; Gonçales FL; Stucchi RSB; Vigani AG
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):959-966. PubMed ID: 29727388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
    Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
    Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?
    Chan WK; Nik Mustapha NR; Mahadeva S; Wong VW; Cheng JY; Wong GL
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1787-1794. PubMed ID: 29603365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new non-invasive method for assessing steatosis in chronic liver diseases].
    Bakulin IG; Sandler YG; Keyan VA; Rotin DL
    Ter Arkh; 2016; 88(2):49-57. PubMed ID: 27030184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
    Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
    World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity.
    Runge JH; van Giessen J; Draijer LG; Deurloo EE; Smets AMJB; Benninga MA; Koot BGP; Stoker J
    Eur Radiol; 2021 Mar; 31(3):1588-1596. PubMed ID: 32910234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
    Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
    Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.